Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development

MLA

David Joseph Bartkovitz, et al. “Discovery of Potent and Orally Active P53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development.” ACS Medicinal Chemistry Letters, vol. 5, no. 2, Sept. 2013. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4edda7a2b95f5842826d5251c317e1a4&authtype=sso&custid=ns315887.

APA

David Joseph Bartkovitz, Packman Kathryn E, Qingjie Ding, Jing Zhang, Xin-Jie Chu, Christian Tovar, Nan Jiang, Jin-Jun Liu, Lyubomir T. Vassilev, Brian Higgins, Sung-Sau So, Prabha Karnachi, Zhuming Zhang, Zoran Filipovic, Bradford Graves, & Kelli Glenn. (2013). Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development. ACS Medicinal Chemistry Letters, 5(2).

Chicago

David Joseph Bartkovitz, Packman Kathryn E, Qingjie Ding, Jing Zhang, Xin-Jie Chu, Christian Tovar, Nan Jiang, et al. 2013. “Discovery of Potent and Orally Active P53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development.” ACS Medicinal Chemistry Letters 5 (2). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....4edda7a2b95f5842826d5251c317e1a4&authtype=sso&custid=ns315887.